$A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma$

A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma

Supplemental Digital Content is available in the text. Bimiralisib is an orally bioavailable pan‐phosphatidylinositol 3‐kinase and mammalian target of rapamycin inhibitor which has shown activity against lymphoma in preclinical models. This phase I/II study evaluated the response rate to bimiralisib...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	HemaSphere 2021-11, Vol.5 (11), p.e656-n/a
Hauptverfasser:	Collins, Graham P., Eyre, Toby A., Schmitz‐Rohmer, Debora, Townsend, William, Popat, Rakesh, Giulino‐Roth, Lisa, Fields, Paul A., Krasniqi, Fatime, Soussain, Carole, Stathis, Anastasios, Andjelkovic, Nebojsa, Cunningham, David, Mandic, Danijela, Radulovic, Sinisa, Tijanic, Ivan, Horowitz, Netanel A., Kurtovic, Sabira, Schorb, Elisabeth, Schmidt, Christian, Dimitrijević, Saša, Dreyling, Martin
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!